Dr. Michael Henderson serves as the Chief Executive Officer and Director of Apogee Therapeutics, guiding the clinical-stage biotechnology enterprise through its research milestones, strategic financing rounds, and the high-profile acquisition agreement with AbbVie. He brings extensive executive experience in life sciences and biopharmaceutical corporate development.